FDA Has Concerns on 'Unprecedented' Plan for Dostarlimab in Rectal Cancer
(MedPage Today) -- The FDA's Oncologic Drugs Advisory Committee (ODAC) will meet Thursday and vote on whether the clinical development plans for dostarlimab (Jemperli) are sufficient to support accelerated approval of the drug for the treatment...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Cancer | Cancer & Oncology | International Medicine & Public Health | Rectal Cancers